| I-03 Khaled Abduljalil Integrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice Wednesday 09:50-11:15 |
| I-04 Anson Abraham Lack of pre-clinical target pharmacology: How to predict first-in-human trial dose(s) and inform clinical trial design? Wednesday 09:50-11:15 |
| I-07 Oliver Ackaert Characterizing exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, in healthy and castration-resistant prostate cancer subjects Wednesday 09:50-11:15 |
| I-10 Maurice Ahsman A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy Wednesday 09:50-11:15 |
| I-18 Usman Arshad A semi-mechanistic pharmacokinetic-pharmacodynamic model of 5-fluorouracil continuous infusion in gastrointestinal cancer patients Wednesday 09:50-11:15 |
| I-25 LE Ba Hai Population pharmacokinetic model of sorafenib and application to a case report Wednesday 09:50-11:15 |
| I-38 Aliénor Bergès Importance of Quantifying Neutropenia Risk Factors in Phase I Solid Malignancy Dose Finding; A Simulation Case Wednesday 09:50-11:15 |
| I-43 Bruno Bieth Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer Wednesday 09:50-11:15 |
| I-47 Elisa Borella Development of a Target-Mediated Drug Disposition Model for the Prediction of Target Occupancy of MEN1112, an Anti Bst1/CD157 Humanized Antibody for the Treatment of Acute Myeloid Leukaemia Wednesday 09:50-11:15 |
| I-51 Muriel Boulton What is the proportion of abiraterone acetate effect on radiographic Progression-Free-Survival (rPFS) explained by Prostate‐Specific Antigen (PSA) kinetics in metastatic castration-resistant prostate cancer (mCRPC)? Wednesday 09:50-11:15 |
| I-55 Núria Buil Bruna Can monocyte counts predict future drug-induced neutropenia toxicities? Wednesday 09:50-11:15 |
| I-60 Tim Cardilin Tumor Static Exposure for anticancer combinations in early drug discovery Wednesday 09:50-11:15 |
| I-71 Viji Chelliah Mechanistic models of cancer-immune cycle and immunotherapies Wednesday 09:50-11:15 |
| I-74 Siri Kalyan Chirumamilla Application of physiologically-based pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients Wednesday 09:50-11:15 |
| I-86 Oleg Demin Jr Investigation of dose response behavior of bispecific T-cell engaging antibodies using quantitative systems pharmacology modeling Wednesday 09:50-11:15 |
| I-87 Laure Deyme Optimizing FOLFIRINOX regimen in pancreatic adenocarcinoma using a 5FU-PKPD model of neutropenia including G-CSF rescue Wednesday 09:50-11:15 |
| II-05 Sofiene Laarif Quantitative modeling of inter-lesion and inter-organ variability of tumor size Wednesday 15:10-16:40 |
| II-24 Aurelie Lombard Tumour size measurements: impact of inter-operator variability on model-based drug effect evaluation Wednesday 15:10-16:40 |
| II-31 Sreenath M Krishnan A combined population kinetic-pharmacodynamic-overall survival model for docetaxel and paclitaxel in the treatment of HER2–negative metastatic breast cancer patients Wednesday 15:10-16:40 |
| II-41 Paolo Mazzei Prospective Evaluation of a Model-Based approach to select Phase 1 Dosing Regimen for MEN1309/OBT076, a novel antibody drug conjugate (ADC) targeting Ly75 antigen for the treatment of CD205-positive metastatic solid tumours and Non-Hodgkin lymphoma Wednesday 15:10-16:40 |
| II-46 Matilde Merino-Sanjuán Impact of ABC gene single nucleotide polymorphisms in population pharmacokinetic of capecitabine and its metabolites 5'-deoxy-5-fluorouridine (5'-DFUR) 5-fluorouracil (5-FU) in patients with colorectal cancer Wednesday 15:10-16:40 |
| II-53 Anna Mc Laughlin Model-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics Wednesday 15:10-16:40 |
| II-58 Ida Neldemo The tumor time-course predicts the overall survival in non-small cell lung cancer patients treated with atezolizumab in a large Phase I study: an evaluation of using different censoring times Wednesday 15:10-16:40 |
| II-60 Laurent Nguyen Pharmacokinetic time-dependency and covariates modelling of Isatuximab monoclonal antibody in multiple myeloma patients: analysis from pooled phase I/II & phase III studies Wednesday 15:10-16:40 |
| II-66 Fernando Ortega Developing a head and neck cancer model to assess the effect of radiotherapy on tumour growth inhibition and regrowth Wednesday 15:10-16:40 |
| II-71 Christophe Passot A kinetic-pharmacodynamic model of palbociclib reveals an influence of body weight on neutropenia onset. Wednesday 15:10-16:40 |
| II-73 Carlos Perez-Ruixo Exposure-response relationships of the efficacy and safety of apalutamide (APA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Wednesday 15:10-16:40 |
| II-76 Chiara Piana Development of a translational pharmacokinetic-biomarker-efficacy model in mouse to support dose recommendation in human Wednesday 15:10-16:40 |
| II-83 Alicja Puszkiel Population pharmacokinetic analysis of tamoxifen and its six metabolites in breast cancer patients: Quantification of the impact of genetic polymorphisms and co-medications on tamoxifen metabolism Wednesday 15:10-16:40 |
| III-30 Mark Stroh Translation and Mechanistic Corroboration of the Preliminary Clinical Pharmacokinetics and Pharmacodynamics of a Masked, Tumor‑Activated anti-PD-L1 Antibody with Systems Pharmacology Thursday 09:55-11:20 |
| III-46 Iñaki F. Trocóniz A modelling platform for onco-immunological drugs in early drug development Thursday 09:55-11:20 |
| III-52 Cristina Vaghi Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor Thursday 09:55-11:20 |
| III-54 Arthur Van De Vyver in vitro PK/PD modeling of immunological synapse-based tumor cell killing and immune activation to predict in vitro efficacy of T-Cell Bispecifics. Thursday 09:55-11:20 |
| III-56 Jan-Stefan van der Walt A Population Pharmacokinetic Analysis to Explore the Effect of Hepatic Impairment on Abemaciclib Pharmacokinetics Thursday 09:55-11:20 |
| III-59 Filippo Venezia Preclinical Pharmacokinetic/Pharmacodynamic modeling to evaluate combination efficacy and the modification effect of oncology compounds with anti-angiogenic drugs (Sunitinib, Axitinib) Thursday 09:55-11:20 |
| III-75 Mélanie Wilbaux Projecting MIW815 (ADU-S100) human tumor PK after intra-tumoral injection using a translational modeling approach combining pre-clinical and clinical data Thursday 09:55-11:20 |
| III-77 Francis Williams Ojara Time-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy Thursday 09:55-11:20 |
| III-83 Anyue Yin Population pharmacokinetics and pharmacogenetics analysis of mitotane in adrenocortical carcinoma patients towards individualized dosing Thursday 09:55-11:20 |
| III-85 Sirin Yonucu Explaining inter-species differences to anti-PDL1 cancer immunotherapy using a translational quantitative systems pharmacology approach Thursday 09:55-11:20 |
| III-86 Jurij Aguiar Zdovc Population pharmacokinetic modeling of cisplatin in patients with small cell lung cancer using informative priors Thursday 09:55-11:20 |
| IV-02 Anne-Gaelle Dosne Exposure-response analysis of erdafitinib and pharmacodynamic-guided dose individualization in patients with locally advanced or metastatic urothelial carcinoma Thursday 15:25-16:50 |
| IV-23 Fanny Gallais Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies Thursday 15:25-16:50 |
| IV-26 Sergey Gavrilov Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer Thursday 15:25-16:50 |
| IV-34 Katharina Martha Götz Predictive Systems Medicine Modelling of Myelosuppression and Recovery of Hematopoietic Cells among Adult Patients with Hematopoietic Cell Transplantation Thursday 15:25-16:50 |
| IV-37 Ana-Marija Grisic Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study Thursday 15:25-16:50 |
| IV-45 Farina Hellmann Population pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example Thursday 15:25-16:50 |
| IV-57 Hiroyuki Iida Modelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice Thursday 15:25-16:50 |
| IV-68 Felix Jost Application of a feedback optimal control algorithm to a population pharmacokinetic-pharmacodynamic model of cytarabine-derived and lenograstim-reduced myelosuppression in acute myeloid leukemia Thursday 15:25-16:50 |
| IV-76 Hidefumi Kasai Tumor Response Index (TRI): model-based prediction of tumor response and survival in metastatic colorectal cancer patients treated by mFOLFOX6 with bevacizumab Thursday 15:25-16:50 |
| IV-85 Lena Klopp-Schulze Exposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development Thursday 15:25-16:50 |
